ACONAclarion, Inc.
The Read
Aclarion's stock historically reacted with a median absolute move of ~23%.
The schedule
- Thu15Oct
The deadline for Aclarion to confirm ongoing compliance with Nasdaq's minimum bid price and equity requirements following recent corporate actions.
- Fri12Feb
Expected disclosure of early interim results from the CLARITY trial, alongside Q3 2026 financial results, serving as a dual-catalyst for validating their diagnostic AI.
- Wed12May
- Sat15May
Aclarion will issue its Q4 2026 results, focusing on full-year cash runway projections and the scaling of its NOCISCAN SaaS installations.
Past
- Thu10Sep
Actual outcome: Mixed · $2.58 at outcome
Price at outcome date was between bear floor ($1.30) and bull target ($2.80).
Aclarion expects an update on its CMS reimbursement pathway for the NOCISCAN suite, a vital hurdle for accelerating commercial adoption and recurring revenue.
- Thu13Aug
Actual outcome: Bull · $2.66 at outcome
Aclarion reported Q2 earnings in line with estimates, with an EPS actual of -1.34 vs estimate -1.34. The stock rallied due to positive strategic developments, including the receipt of a patent notice and the announcement of Nociscan availability at key medical centers, signaling progress in commercialization and IP protection.
Q2 2026 financial results detailing hospital adoption rates and initial scaling metrics for their diagnostic software.
- Mon20Jul
Actual outcome: Bear · $2.45 at outcome
Despite announcing the presentation of two abstracts highlighting Nociscan's growing role in clinical practice, Aclarion shares fell 6.8% toward the bear floor. The clinical update failed to alleviate underlying market concerns regarding the company's cash burn and the looming threat of a dilutive secondary equity offering to fund operations.
With ongoing cash burn typical of early-stage commercialization, the market is bracing for a potential secondary equity offering or ATM execution to fund operations through upcoming clinical milestones.
- Wed13May
Actual outcome: Bear · $3.19 at outcome
Aclarion reported a Q1 loss of $1.34 per share, which beat the consensus estimate of a $1.55 loss, but the company missed revenue expectations. Despite positive operational momentum leading into the print—such as a second commercial agreement with Weill Cornell Medicine and the expansion of its CLARITY trial—the mixed financial results and ongoing cash runway concerns kept investors on the sidelines. Consequently, the stock saw a muted reaction, declining just 2.7% by the outcome date.
Q1 2026 earnings report focusing on revenue inflection and the critical cash runway, given the ongoing $1.8M average quarterly net loss.
